China SXT Pharmaceuticals (FRA:2RY1) Tariff Resilience Score: 3/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2RY1 China SXT Pharmaceuticals Inc FRA:2RY1
40 GF Score
Price €0.04
GF Value €1.16
! 8 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals Tariff Resilience Score?

China SXT Pharmaceuticals FRA:2RY1 40 Tariff Resilience Score is 3 as of Jul. 25, 2026. GuruFocus rates FRA:2RY1 with a GF Score™ of 40/100 and a GF Value™ of €1.16. The stock has 8 warning signs investors should review. Among 1,026 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 77.39% on this metric.

China SXT Pharmaceuticals has the Tariff Resilience Score of 3, which implies that the company might have .

China SXT Pharmaceuticals has Heavily reliant on Chinese manufacturing and exports, with limited diversification in supply chain. Previous tariffs on pharmaceuticals have impacted costs. Limited pricing power in competitive market.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes China SXT Pharmaceuticals might have .

China SXT Pharmaceuticals  (FRA:2RY1) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

China SXT Pharmaceuticals Tariff Resilience Score Related Terms

FRA:2RY1 vs CABR, BFRI, BIOE: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Tariff Resilience Score falls into.


FRA:2RY1
40GF Score
China SXT Pharmaceuticals Inc FRA:2RY1
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 3 mean?
China SXT Pharmaceuticals (FRA:2RY1) has a Tariff Resilience Score of 3 as of Jul. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, China SXT Pharmaceuticals ranks #232 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is China SXT Pharmaceuticals' Tariff Resilience Score too high?
China SXT Pharmaceuticals' current Tariff Resilience Score is 3. Based on the distribution chart, China SXT Pharmaceuticals ranks #232 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Tariff Resilience Score compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #232 out of 1026 companies for Tariff Resilience Score. This places China SXT Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. China SXT Pharmaceuticals's current Tariff Resilience Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY1) has a current Tariff Resilience Score of 3. The stock's GF Value™ is €1.16, compared to a current price of €0.04 — trading 96.9% below its estimated fair value. The current Tariff Resilience Score is 3. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY1), the current Tariff Resilience Score is 3 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (FRA:2RY1) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued. The current stock price of €0.04 is trading 96.9% below its estimated GF Value™ of €1.16.

Key valuation signals for FRA:2RY1:

  • Tariff Resilience Score: 3
  • GF Value™: €1.16 vs. price of €0.04 (96.9% below fair value)
  • GF Score™: 40/100 with 8 warning signs

No single metric tells the full story. See the FRA:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score

Get the complete analysis for FRA:2RY1

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€1.16
GF Value